Yourgene Health PLC - Manchester, England-based molecular diagnostics company - Says that the strong trading seen in first half has continued in the second half. Covid-19 testing laboratory in the Citylabs 1.0 health innovation hub in Manchester was deployed heavily over the winter season. Adds that its new Covid-19 sequencing servicer has launched and was awarded a contract by the UK Health Security Agency. Says it is scaling up this service for additional volume as it has made a "strong" contribution.
Believes full-year revenue and adjusted earnings before interest, tax, depreciation, and amortization will exceed already raised market expectations. Expects to report annual revenue of at least GBP37 million, 28% above market expectations of GBP29 million. Anticipates adjusted Ebitda margins to be at least 10%, which will deliver a positive swing of over GBP5.5 million from GBP2.0 million loss the year before.
Current stock price: 11.94 pence
12-month change: down 16%
By Abby Amoakuh; abbyamoakuh@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
